Henan Lingrui Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600285.SS

Henan Lingrui Pharmaceutical Co., Ltd. EBIT Margin for the year ending December 31, 2023: 19.75%

Henan Lingrui Pharmaceutical Co., Ltd. EBIT Margin is 19.75% for the year ending December 31, 2023, a 15.12% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Henan Lingrui Pharmaceutical Co., Ltd. EBIT Margin for the year ending December 31, 2022 was 17.16%, a 16.41% change year over year.
Henan Lingrui Pharmaceutical Co., Ltd. EBIT Margin for the year ending December 31, 2021 was 14.74%, a 10.27% change year over year.
Henan Lingrui Pharmaceutical Co., Ltd. EBIT Margin for the year ending December 31, 2020 was 13.37%, a -19.30% change year over year.
Henan Lingrui Pharmaceutical Co., Ltd. EBIT Margin for the year ending December 31, 2019 was 16.56%, a 14.82% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Shanghai Stock Exchange: 600285.SS

Henan Lingrui Pharmaceutical Co., Ltd.

CEO	Mr. Wei Xiong
IPO Date	Oct. 18, 2000
Location	China
Headquarters	No.666 Jiangjun Road
Employees	2,530
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Henan Lingrui Pharmaceutical Co., Ltd. produces and sells medicines in China. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, tinctures, etc. covering approximately 100 product varieties. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, Shenqi Hypoglycemic capsules, and others. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is based in Xinyang, China.

Key trends

Past 5 years